The prognostic impact of tumour NSD2 expression in advanced prostate cancer.
CONCLUSION: NSD2 expression is abnormal in almost 80% of patients with advanced PCa. Expression levels of this epigenetic regulator are easily detected by immunohistochemistry while this biomarker exhibited prognostic value for PCa progression and death in univariable analysis. Further studies on NSD2 involvement in PCa proliferation, progression, metastasis and resistance mechanisms are needed. PMID: 32091270 [PubMed - as supplied by publisher]
Madam — Historically, effective systemic treatments for men diagnosed with advanced or metastatic prostate cancer were limited. Most would experience an initial but temporary symptomatic and biochemical response to castration-based therapy with either bilateral orchidectomy or luteinising hormone-releas ing hormone agonists. At this stage, the addition of antiandrogens, steroids, stilboestrol or chemotherapy with mitoxantrone could be considered. These agents had short-lived benefits with no improvement in survival and limited symptomatic or palliative response for bone pain.
CONCLUSIONS: The allocation to curative and palliative strategies should be made according to patient and tumor characteristics by definition. Palliative procedures may represent concepts in older patients who initially chose a curative AS strategy. PMID: 32025749 [PubMed - as supplied by publisher]
We report updated outcomes of ultrafocal salvage high-dose-rate brachytherapy (HDR-BT).
Abstract BACKGROUND AND PURPOSE: To investigate associations between socio-demographic characteristics and radiotherapy patterns of care in non-metastatic prostate cancer [nmPCa] in South Australia [SA] between 2005-2015 and document practice patterns over time. MATERIALS AND METHODS: Men with nmPCa receiving primary curative radiotherapy were identified from SA Prostate Cancer Clinical Outcomes Collaborative database. Adjuvant, salvage and palliative therapies were excluded. Associations between socio-demographic factors (age, residence, socio-economic status, diagnostic period) and radiotherapy mode (extern...
Cascante M Abstract Platinum-based chemotherapy persists to be the only effective therapeutic option against a wide variety of tumours. Nevertheless, the acquisition of platinum resistance is utterly common, ultimately cornering conventional platinum drugs to only palliative in many patients. Thus, encountering alternatives that are both effective and non-cross-resistant is urgent. In this work, we report the synthesis, reduction studies and luminescent properties of a series of cyclometallated (C,N,N') PtIV compounds derived from amine-imine ligands, and their remarkable efficacy at the high nanomolar range and ...
ConclusionsMaxillofacial manifestation of bone metastasis is common but is often overlooked. Therefore, it should be considered in the differential diagnosis when a patient with a history of antiresorptive medications presents with a gingival mass and/or exophytic bone. Good clinical judgment and well-timed bone biopsy and diagnostic imaging can lead to the correct diagnosis and optimal treatment.
CONCLUSION: Treatment with 177Lu-PSMA has emerged as a promising systemic modality, which involves the delivery of targeted radiation therapy in the form of β-particles to sites of tumour tissue. Therapy is provided on an outpatient basis, is well tolerated with relatively few side effects and has a positive effect on overall survival and quality of life. At present, it is used mostly in the setting of advanced, castrate-resistant cancer. Patients are selected (amongst other criteria) based on the prior PSMA-based SPECT/PET/CT imaging (99mTc-,68Ga- or 18F-PSMA), which should demonstrate sufficient receptor expression ...
ConclusionClinical interventions for improving symptoms should focus particularly on the first year after prostate cancer diagnosis. Greater emphasis on improving sexual function should be practiced in clinical and rehabilitative care, since this area has the single greatest impact on symptom-specific QoL after primary treatment for prostate cancer.
CONCLUSIONS: In France, end-of-life management of men with PCa, regardless of the cause of death, is centered on SSH and HPC, essentially at the time of death. Certain indicators of end-of-life management were particular high. LEVEL OF EVIDENCE: 4. PMID: 31708329 [PubMed - as supplied by publisher]
Prostate Cancer and Prostatic Diseases, Published online: 04 November 2019; doi:10.1038/s41391-019-0183-9Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies